Kanaph Therapeutics

About Kanaph Therapeutics

Kanaph Therapeutics, a South Korean-based biotechnology firm in its pre-clinical stage, was established in 2019 by a team with extensive experience in drug development. The company is spearheaded by Byoung-chul (BC) Lee, who serves as the CEO. Prior to Kanaph, he held significant roles at LegoChem Biosciences, including Head of the Bio-therapeutics business unit and Senior Vice President. Another key figure is Chief Technology Officer Hobin Kim, who previously led the antibody-drug conjugate (ADC) R&D team at LegoChem Biosciences. The company pursues a dual-strategy approach, advancing both large and small molecule drug candidates. Its core focus lies in developing treatments for immuno-oncology, targeted cancer therapy, and autoimmune diseases, particularly in the field of ophthalmology. Kanaph Therapeutics has secured notable funding to advance its pipeline, including a Series A round of $6 million in 2019 and a subsequent Series B financing of $21 million in 2021. These financial milestones have enabled the firm to progress its proprietary drug candidates through the crucial pre-clinical phases. Kanaph's oncology pipeline features bi-specific antibodies and small molecules engineered to amplify the immune response within the tumor micro-environment, aiming for more effective tumor destruction. For autoimmune disorders, the company is developing bispecific Fc-fusion proteins. These proteins are designed to block the alternative complement pathway, a key driver of inflammation, while also inhibiting angiogenesis (the formation of new blood vessels) and other complement activation processes. A significant development is their drug candidate, TMEkine, which combines an anti-PD-L1 antibody with a T-cell-activating cytokine, creating a bi-specific antibody designed to enhance anti-tumor effects. The business model centers on the discovery and pre-clinical development of novel drug candidates. The ultimate goal is to partner with or license these assets to larger pharmaceutical companies for clinical development and commercialization. This strategy is common for biotech startups, allowing them to focus on their core research and development strengths while leveraging the resources of established players for late-stage trials and market access. Keywords: immuno-oncology, autoimmune diseases, bi-specific antibodies, targeted therapy, small molecules, pre-clinical biotech, oncology pipeline, ophthalmology, alternative complement pathway, tumor micro-environment